Vivex Biomedical - About the company
Vivex Biomedical is a series A company based in Marietta (United States), founded in 2012. It operates as an Allograft solutions for musculoskeletal injuries, wound care, and interventional pain. Vivex Biomedical has raised $20.5M in funding. The company has 127 active competitors, including 35 funded and 24 that have exited. Its top competitors include companies like Tenaya Therapeutics, Pandorum and Athira Pharma.
Company Details
Allograft solutions for musculoskeletal injuries, wound care, and interventional pain. They develop and deliver innovative allografts designed to support the body’s healing potential to help improve patient outcomes and quality of life. Their diverse portfolio of allografts are utilized in patients suffering from musculoskeletal injuries, chronic wounds, and burned and injured skin. They process, store, and distribute Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) and distributes medical devices to hospitals, medical professionals, and approved distributors. They offer products by therapy, including ortho & fusion therapies, wound care & amnion therapies, and interventional pain therapies. Product types include amniotic membrane allografts, DBM cancellous sponges & strips, DBM fibers, DBM paste with chips, DBM putty, moldable bone graft substitutes, spine allografts, and viable allogeneic bone matrices. They partner with recovery services for tissue donations and provide educational resources.
- Website
- vivex.com
- Social
- Registered Address
- Atlanta,Georgia
Key Metrics
Founded Year
2012
Location
Marietta, United States
Stage
Series A
Total Funding
$20.5M in 4 rounds
Latest Funding Round
Investors
Ranked
32nd among 127 active competitors
Employee Count
258 as on May 31, 2026
Similar Companies
Legal entities associated with Vivex Biomedical
Vivex Biomedical is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
VIVEX BIOMEDICAL, INC. CIN: 461175674 , United States, Active | Dec 31, 1999 | $25M - $100M (As on May 11, 2017) | 396 (As on Dec 31, 2024) | - |
VIVEX CIN: 40003974809 , Latvia, Active | Dec 03, 2007 | €0 - €1M (As on Dec 31, 2024) | 3 (As on Dec 31, 2023) | - |
Sign up to download Vivex Biomedical's company profile
Vivex Biomedical's funding and investors
Vivex Biomedical has raised a total funding of $20.5M over 4 rounds. Its first funding round was on Sep 16, 2013. Vivex Biomedical has 5 institutional investors.
Here is the list of recent funding rounds of Vivex Biomedical:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 11, 2017 | 6446836 | Series A | 6547410 | 5540339 | 8968044 | 4314141 |
Apr 05, 2017 | 2988361 | Conventional Debt | 4206619 | 2743397 | 3661546 | |
Jan 05, 2016 | 4874790 | Series A | 6088756 | 6500429 | 3482011 | 1273285 |
Access funding benchmarks and valuations. Sign up today!View details of Vivex Biomedical's funding rounds and investors
Vivex Biomedical's founders and board of directors
Founder? Claim ProfileVivex Biomedical's employee count trend
Vivex Biomedical has 258 employees as of May 26. Here is Vivex Biomedical's employee count trend over the years:
Uncover Vivex Biomedical's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Vivex Biomedical's Competitors and alternates
Top competitors of Vivex Biomedical include Tenaya Therapeutics, Pandorum and Athira Pharma. Here is the list of Top 10 competitors of Vivex Biomedical, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Tenaya Therapeutics 2016, San Francisco (United States), Public | Developer of regenerative and gene therapeutics for heart failure | $248M | 70/100 | |
2nd | Developer of regenerative medicine and 3D tissues | $52.1M | 65/100 | ||
3rd |  Athira Pharma 2011, Seattle (United States), Public | Developer of drugs for neurodegenerative diseases | $121M | 65/100 | |
4th |  Tune Therapeutics 2009, Seattle (United States), Series B | Developer of cell and gene therapy by using the epigenomic platform | $222M | 63/100 | |
5th | Orca Bio 2016, Menlo Park (United States), Series F | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | $300M | 63/100 | |
6th | LIfT Biosciences 2016, London (United Kingdom), Series A | Developer of neutrophil-based cell therapies for solid tumors | $20.1M | 61/100 | |
7th |  Stellular Bio 2014, Watertown (United States), Series A | Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells | $37.5M | 61/100 | |
8th | Avita Medical 1992, Cambridge (United Kingdom), Public | Regenerative and Respiratory Medicine product company | - | 59/100 | |
9th | Orthofix 1980, Lewisville (United States), Public | Developer of reconstructive and regenerative solutions for bone-related conditions | - | - | 59/100 |
10th | TreeFrog Therapeutics 2018, Talence (France), Series B | Developer of stem cells and organoids using proprietary technology | $84.2M | 59/100 | |
32nd | Vivex Biomedical 2012, Marietta (United States), Series A | Allograft solutions for musculoskeletal injuries, wound care, and interventional pain | $20.5M | 44/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Vivex Biomedical's competitors? Click here to see the top ones
Vivex Biomedical's Investments and acquisitions
Vivex Biomedical has made no investments or acquisitions yet.
Reports related to Vivex Biomedical
Here is the latest report on Vivex Biomedical's geography:
News related to Vivex Biomedical
•
Vivex Biologics Appoints Jon E. Block as Chief Clinical OfficerBenzinga•Jun 10, 2025•Vivex Biomedical
•
Premia Spine Appoints Three New Board AdvisorsMedical Device News•Dec 08, 2021•Premia Spine, Vivex Biomedical, Johnson & Johnson
•
•
•
Former Titan Spine executive joins Vivex BiologicsBeckersspine•Feb 14, 2020•Vivex Biomedical, Titan Spine
•
Atlanta Biomedical Company Hires Second New CEO in Less Than a YearMetro Atlanta CEO•Sep 24, 2019•Vivex Biomedical
•
Vivex Biomedical, Inc. announces Lisa Colleran as the new CEO of the companyPR Newswire•Oct 23, 2018•Vivex Biomedical
•
Vivex Biomedical, Inc. Announces Peer-Reviewed Study of VIA GraftPR Newswire•May 04, 2018•Vivex Biomedical
•
Vivex Biomedical Receives $9m Credit LineFinSMEs•Apr 06, 2017•Vivex Biomedical, Heritage Bank of Commerce
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Vivex Biomedical
Explore our recently published companies
- Autocal - Thane based, 2002 founded, Funding Raised company
- Indo Amines - Thane based, 1994 founded, Public company
- Taro International - Haifa based, 1992 founded, Unfunded company
- SmartCart AI - San Francisco based, Unfunded company
- 365 Retail Markets - London based, 2008 founded, Unfunded company
- Bishop Paiute Development Corporation - Bishop based, 2009 founded, Funding Raised company
